Status: Not yet recruiting
Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients
The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for follow-up assessments
Participants needed: 44
Trial details
Phase: Phase 3Age: 2-65Biological sex: AllType: InterventionalSponsor: Virchow GroupUpdated: Jun 12, 2025Locations: 2
Eligibility criteria
Male or female, aged 2 to 65 years. [+11]
Pregnant women, nursing mothers or a planned pregnancy within 18 months of parti... [+15]